Delestrain C, Flamein F, Jonard L, Couderc R, Guillot L, Fanen P, Epaud R
Inserm, U955, équipe 11, 94000 Créteil, France.
Rev Pneumol Clin. 2013 Aug;69(4):183-9. doi: 10.1016/j.pneumo.2013.05.002. Epub 2013 Jul 12.
Pulmonary surfactant is a unique mixture of lipids and specific proteins that reduces surface tension at the air-liquid interface, preventing collapse of the lung at the end of expiration. Recessive loss-of-function mutations of pulmonary surfactant protein B (SP-B) was initially described in infants who develop respiratory failure at birth. More recently, mutations in other constitutive surfactant proteins like surfactant protein C or implied in its metabolism like ATP-binding cassette, sub-family A, member 3 (ABCA3) or NK2 homeobox (NKX2-1) were identified in newborn with respiratory distress but also in children with diffuse infiltrative pneumonia. Intra-alveolar accumulation of protein related to surfactant dysfunction leads to cough, hypoxemia and radiological abnormalities including ground-glass opacities and lung cysts. The clinical and radiological features associated with these genetic disorders, along with their treatment and outcome, are reviewed.
肺表面活性物质是脂质和特定蛋白质的独特混合物,可降低气液界面的表面张力,防止肺在呼气末塌陷。肺表面活性物质蛋白B(SP-B)的隐性功能丧失突变最初在出生时发生呼吸衰竭的婴儿中被描述。最近,在患有呼吸窘迫的新生儿以及患有弥漫性浸润性肺炎的儿童中,发现了其他组成型表面活性物质蛋白(如表面活性物质蛋白C)或其代谢相关蛋白(如ATP结合盒A亚家族成员3(ABCA3)或NK2同源盒(NKX2-1))的突变。与表面活性物质功能障碍相关的蛋白质在肺泡内积聚导致咳嗽、低氧血症和包括磨玻璃影和肺囊肿在内的放射学异常。本文综述了与这些遗传疾病相关的临床和放射学特征,以及它们的治疗方法和预后。